Podcast appearances and mentions of Paul P Doghramji

Please visit answersincme.com/DCF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in chronic kidney disease discuss the importance of early detection and optimized management by both primary care physicians and nephrologists. Upon completion of this activity, participants should be better able to: Identify the role of timely assessment and early diagnosis in optimizing outcomes in patients with chronic kidney disease (CKD); Describe approved and emerging pharmacologic treatment options for patients with CKD; and Outline patient-centered strategies to maximize patient care in CKD.

Host: Paul P. Doghramji, MD, FAAFP Guest: Joshua Ofman, MD, MSHS Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.

Host: Paul P. Doghramji, MD, FAAFP Guest: Joshua Ofman, MD, MSHS Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.

Guest: Rana McKay, MD Host: Paul P. Doghramji, MD, FAAFP Dr. Rana Mckay, a Medical Oncologist and Assistant Professor of Medicine at the University of California San Diego, explores the role of surveillance and frontline local therapy for patients with advanced renal cell carcinoma

Guest: Wenxin Xu, MD Host: Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji joins Dr. Wenxin Xu, a physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, to take a look at some of the key factors guiding treatment decisions and disease management for patients with advanced renal cell carcinoma.

Host: Paul P. Doghramji, MD, FAAFP Guest: Corey S. Cutler, MD, MPH, FRCPC Guest: Doris M. Ponce, MD Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD?

Host: Paul P. Doghramji, MD, FAAFP Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA The spread of the COVID-19 pandemic has caused us to reconsider how we treat our patients with multiple sclerosis (MS) and even the role of immunosuppression in autoimmunity. How do we decide what the best course of action is, and what does limited research available tell us about making the right treatment decision? Those are the exact questions Dr. Paul Doghramji explores with Dr. Amit Bar-Or.

Host: Paul P. Doghramji, MD, FAAFP Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA The spread of the COVID-19 pandemic has caused us to reconsider how we treat our patients with multiple sclerosis (MS) and even the role of immunosuppression in autoimmunity. How do we decide what the best course of action is, and what does limited research available tell us about making the right treatment decision? Those are the exact questions Dr. Paul Doghramji explores with Dr. Amit Bar-Or.

Guest: Paul Doghramji, MD Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences. Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice. This promotional, non-CME program is intended for U.S. physicians treating OSA. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-2000467 Rev0920

Guest: Paul Doghramji, MD Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences. Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice. This promotional, non-CME program is intended for U.S. physicians treating OSA. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-2000467 Rev0920

Insomnia is a highly prevalent condition that presents in primary care, but nearly three quarters of all patients do not tell their providers about their symptoms. Unfortunately, insomnia can have serious consequences for patients' daily activities, quality of life, and mental and physical health. Recent developments in the understanding of insomnia have led to the availability of new treatment options, but clinicians may not be aware of these developments. In this episode, Dr. Paul P. Doghramji will discuss the importance of recognizing the condition, examine evidence-based treatment of insomnia, and review the role of orexin in the balance of sleep and wakefulness.Faculty Paul P. Doghramji, MD, FAAFPFamily PhysicianCollegeville Family PracticeMedical Director of Health ServicesCollegeville, PAHostGregg Sherman, MDChief Medical Officer/Course DirectorNational Association for Continuing EducationPlantation, FLThis educational activity is supported by an independent medical educational grant from Eisai.This activity is not certified for CME/CE credit.

Host: Paul P. Doghramji, MD, FAAFP Guest: Edward S. Kim, MD Thanks to recent research, we can now use a non-small cell cancer patient’s cancer type and genomic makeup to create targeted treatment plans. Joining Dr. Paul Doghramji to share what that approach looks like in practice is Dr. Edward Kim, the Chair of Solid Tumor Oncology and Investigational Therapeutics at the Levine Cancer Institute Atrium Health in Charlotte, North Carolina.

Host: Paul P. Doghramji, MD, FAAFP Guest: Edward S. Kim, MD Thanks to recent research, we can now use a non-small cell cancer patient’s cancer type and genomic makeup to create targeted treatment plans. Joining Dr. Paul Doghramji to share what that approach looks like in practice is Dr. Edward Kim, the Chair of Solid Tumor Oncology and Investigational Therapeutics at the Levine Cancer Institute Atrium Health in Charlotte, North Carolina.

Go online to PeerView.com/HQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in insomnia management discusses strategies for improving the recognition and treatment of insomnia in the primary care setting. Upon completion of this activity, participants should be better able to: Describe the impact of insomnia on quality of life and risk of psychiatric and physical illnesses, Differentially diagnose insomnia from other sleep disorders, Identify tolerance and dependency issues and adverse events associated with available insomnia therapies, Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia

Go online to PeerView.com/HQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in insomnia management discusses strategies for improving the recognition and treatment of insomnia in the primary care setting. Upon completion of this activity, participants should be better able to: Describe the impact of insomnia on quality of life and risk of psychiatric and physical illnesses, Differentially diagnose insomnia from other sleep disorders, Identify tolerance and dependency issues and adverse events associated with available insomnia therapies, Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia

Go online to PeerView.com/HQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in insomnia management discusses strategies for improving the recognition and treatment of insomnia in the primary care setting. Upon completion of this activity, participants should be better able to: Describe the impact of insomnia on quality of life and risk of psychiatric and physical illnesses, Differentially diagnose insomnia from other sleep disorders, Identify tolerance and dependency issues and adverse events associated with available insomnia therapies, Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia

Host: Paul P. Doghramji, MD, FAAFP Guest: Alexander W. Pastuszak, MD, PhD While Peyronie’s disease isn’t the most comfortable topic to talk about with your male patients, avoiding it only fuels its under-recognition. So joining Dr. Paul Doghramji to discuss conversation-starter strategies—and what to do once you have that conversation and reach a diagnosis—is Dr. Alexander Pastuszak, a urologist at the University of Utah School of Medicine in Salt Lake City who specializes in the treatment of male infertility and sexual dysfunction.